Print
Email
Print Edition StoriesTuesday, October 21, 2008
Neurotech Pharmaceuticals opens Cumberland, R.I., facility
By Mass High Tech Staff
Optical therapeutics firm Neurotech Pharmaceuticals Inc. has opened in Cumberland, R.I., a 27,000-square-foot GMP manufacturing facility for the biotech’s chronic retinal disease treatments. Neurotech received $4 million in funding from the Rhode Island Economic Development Corp. and its units, Rhode Island Industrial Facilities Corp. and Rhode Island Industrial-Recreational Building Authority.
Neurotech produces NT-501, a treatment focused on releasing Ciliary Neurotrophic Factor (CNTF) proteins into the eye to improve Retinitis Pigmentosa and age-related macular degeneration. Neurotech officials report the role of CNTF in reviving dying retinal photoreceptors.
Neurotech completed Phase 1 clinical trials of the NT-501 in 2006, with results showing safe usage in a six-month time period. The product now stands to be tested in Phase 2 and Phase 2/3 clinical trials, which have just completed enrollment, according to Neurotech’s website.
Lincoln, R.I.-based Neurotech USA Inc. is a wholly owned subsidiary of Neurotech Pharmaceuticals Inc. in Delaware.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
